Cargando…
Management of relapsed ovarian cancer: a review
Around 70 % of ovarian cancer patients relapse after primary cytoreductive surgery and standard first-line chemotherapy. The biology of relapse remains unclear, but cancer stem cells seem to play an important role. There are still some areas of controversy on how to manage these relapses and or prog...
Autor principal: | Giornelli, Gonzalo H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4963348/ https://www.ncbi.nlm.nih.gov/pubmed/27516935 http://dx.doi.org/10.1186/s40064-016-2660-0 |
Ejemplares similares
-
Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer
por: Goh, Jeffrey C.H., et al.
Publicado: (2022) -
Treatment for Recurrent Ovarian Cancer—At First Relapse
por: Ushijima, Kimio
Publicado: (2010) -
Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer
por: Ledermann, Jonathan A., et al.
Publicado: (2019) -
Review of the Management of Relapsed Small-Cell Lung Cancer with Amrubicin Hydrochloride
por: Kimura, Tatsuo, et al.
Publicado: (2011) -
Radiopharmaceuticals for Relapsed or Refractory Ovarian Cancers
por: Kunos, Charles A., et al.
Publicado: (2019)